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Objective: This study evaluated the perioperative and 3-year follow-up results of 103 consecutive carotid artery stenting
(CAS) procedures done with a transcervical approach using carotid flow reversal for cerebral protection that were
performed over a 28-month period in 97 patients.
Methods: The mean age of these patients was 72 years, and 82 (80%) were men. Mean preoperative internal carotid artery
(ICA) peak systolic velocity was 314 cm/s, 36% of treated hemispheres were symptomatic, and 42% of patients had
neurologic symptoms for >6 months. Ten patients (10%) had contralateral ICA occlusion, six (6%) had recurrent carotid
stenosis, and two (2%) had previous neck radiation. Local anesthesia was used in 72 (70%) cases and general in 31 (30%).
Predilatation was used in 34 cases (33%), and closed-cell self-expanding stents were deployed and postdilated in all cases.
Results: Technical success was achieved in 100 cases (97%). No major strokes or deaths occurred. One ipsilateral transient
ischemic attack (1%), one contralateral transient ischemic attack (1%), and two minor strokes (2%) occurred. There were
two wound complications (2%) and one major arterial complication (1%). Mean operative time was 69 minutes, and mean
carotid flow reversal time was 21 minutes. Three awake patients (4%) did not tolerate carotid flow reversal. Hypotension/
bradycardia occurred in 24 cases (23%). No electrocardiographic myocardial infarctions were diagnosed. At 40 months of
follow-up, the stent patency rate on an intention-to-treat basis was 95%, and the stroke-free survival was 91%.
Conclusions: Transcervical CAS with carotid flow reversal can be done with a high rate of technical success, a negligible
rate of major adverse events, and an excellent 3-year stroke-free survival and stent patency rate. These results compare
favorably with those of recently published prospective studies using distal filter protection during CAS. ( J Vasc Surg
2007;46:864-9.)Cerebral embolization is the greatest risk for neuro-
logic complications during carotid artery stenting (CAS).
The use of protection methods to prevent cerebral embo-
lization during CAS is intuitively appealing and has ap-
peared to reduce the incidence of neurologic complications
associated with the procedure.1,2 However, the beneficial
effect of cerebral protection during CAS has not been
proven in controlled, prospective trials. Most major clinical
studies of CAS have used distal filters for cerebral protec-
tion and have compared the neurologic complication rates
with those of carotid endarterectomy (CEA),3-5 but to
date, no controlled studies to the best of our knowledge
have compared the efficacy of distal filter devices against
other methods for cerebral protection during CAS. For this
reason, the optimal cerebral protection method for CAS
has not yet been defined.
Distal filter protection devices are used because of their
ability to capture embolic material during CAS. However,
distal filters have been shown to allow a large number of
microembolic phenomena during the procedure and to be
From the Section of Vascular Surgery, University of Michigan School of
Medicinea; and Complejo Hospitalario de Toledo.b
Competition of interest: none.
Presented in part at the XXXIII Annual VEITH Symposium, New York,
New York, November 19, 2006.
Correspondence: Enrique Criado, MD, Section of Vascular Surgery, Uni-
versity of Michigan School of Medicine, 1500 Medical Center Dr, TC-
2210, Ann Arbor, MI 48109-0329 (e-mail: ecriado@umich.edu).
0741-5214/$32.00
Copyright © 2007 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2007.07.028
864associated with a high incidence of new cerebral infarctions
after stenting.6-8
Compared with distal protection systems, cerebral pro-
tection with carotid flow reversal has advantages that have
been documented in the laboratory and in clinical experi-
ence.9,10 Transcervical CAS with carotid flow reversal has
been shown to produce a remarkably low incidence on
intraprocedural cerebral embolization11 and, in our initial
clinical experience and that of others, a very low procedural
neurologic complication rate.12,13 This report updates the
review of our experience with transcervical CAS with ca-
rotid flow reversal, including 3-year follow-up data.
PATIENTS AND METHODS
FromMarch 2003 to July 2005, 103 consecutive tran-
scervical CAS procedures were performed in 97 patients,
consisting of 52 stents on the right carotid and 51 on the
left. The first 50 cases included in this study were thematter
of a previous report that documented the initial feasibility
and safety of the procedure.12 Medical history, comorbidi-
ties, neurologic status, degree of carotid stenosis, intraop-
erative findings and events, and postoperative follow-up
were prospectively recorded. Patient mean age was 72 years
(range, 54-90 years), and 82 patients (79.6%) were men.
Comorbid medical conditions are summarized in Table I.
Thirty-seven patients (36%) presented with ipsilateral
(6 months old) stroke (14%) or transient ischemic attack
(TIA; 22%). In addition, 43 patients (42%) had a history of
stroke (22%) or TIA (20%) more than 6 months before the
procedure. Preoperative mean ipsilateral internal carotid
peak systolic velocity (PSV) was 314 cm/s (range, 0 to 904
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PSV was 124 cm/s. One patient with 0 velocity was sus-
pected to have an open internal carotid, but a velocity
waveform could not be obtained because of plaque calcifi-
cation. A very tight lesion was confirmed during intraoper-
ative angiography. The duplex estimated degree of stenosis
was 50% for symptomatic patients and 70% for asymp-
tomatic patients.
Patients were offered the procedure because of the
higher risk for general anesthesia or of a major procedure
and on their preference for a less invasive approach. All
cases were done on the basis of preoperative duplex ultra-
sound imaging without preoperative angiography.
All procedures were done exclusively by vascular sur-
geons. Local/regional anesthesia was used in 72 cases
(70%) and general in 31 (30%). Most of the general anes-
thetics (n  25) were used during the first half of this
experience while the technique was developed. Mean op-
erative time was 69 minutes (range, 20 to 180 minutes).
Mean administered contrast agent volume was 51 mL
(range, 10 to 120 mL). All patients were taking clopidogrel
before stent placement. Systemic heparinization was done
with 100 IU/kg of body weight of intravenous heparin.
Our technique for transcervical CAS and interventional
protocol have been previously described.12,14 A mini-
cervical cutdown was used to establish a carotid artery-to-
jugular vein fistula by using commercially available vascular
access sheaths (Fig 1).
Intraoperative diagnostic digital arteriography using
hand injection was performed in the lateral and oblique
planes to localize and quantitate the degree of ICA stenosis
in all cases, revealing a 50% stenosis in six (6%), 70% in 75
(73%), and subocclusive stenosis in 22 (21%). With carotid
artery flow reversal in place, a 0.014-in guidewire (Plati-
num plus TM, ST, 0.014-180 cm; Boston Scientific, Med-
itech, Miami, Fla) in a 4F or 5F  40-cm-long Bernstein
catheter (Angiodynamics, Queensbury, NY) was used to
cross the ICA stenosis under fluoroscopic guidance, and
the tip of the guidewire was advanced to the level of the
carotid siphon. Predilatation of the carotid stenosis with 3-
to 5-mm-diameter balloons was done in 34 cases (33%).
Predilatation was done at the discretion of the operator
based on the estimation that the stent delivery system
Table I. Medical comorbidities in 97 patients
undergoing 103 transcervical carotid stenting procedures
Medical Comorbidity No. %
Hypertension 81 79
Hypercholesterolemia 58 56
Coronary artery disease 35 34
Smoking 25 24
Diabetes mellitus 22 21
Severe COPD 8 8
Renal insufficiency 11 11
Cigarette smoking 25 24
COPD, Chronic obstructive pulmonary disease.would not cross the lesion without predilatation.Self-expandable 7-, 8-, 9- or 10-mm diameter  25-,
30-, or 40-mm-long stents were used, totaling 99 biliary
Wallstent, Monorail stents (Boston Scientific, Maple
Grove, Minn), and five Exponent (Medtronic, Minneapo-
lis, Minn) stents. Two stents were deployed in one carotid
artery. Poststent dilation was performed for 5 to 15 seconds
in all cases with 5-, 5.5-, or 6-mm  2-cm-long monorail
balloon catheters (Ultra-soft SV Monorail Balloon cathe-
ter; Boston Scientific) inflated to 8 atm. Completion arte-
riography was done in all cases to assess technical results
and the presence of distal spasm. Intra-arterial papaverine
solution (1 mg/mL) was selectively used to treat residual
carotid spasm.
After completion, the access sheaths were removed, the
vessel access sites were closed with 5-0 or 6-0 polypro-
pylene suture, and the cervical wound was closed with
absorbable suture. All patients remained under observation
in the recovery room with electrocardiographic monitoring
after the intervention and were transferred to a floor or
telemetry bed when stable. Troponin levels were not rou-
tinely obtained postoperatively, but were not elevated in
two patients with transient asystole in response to balloon
dilatation.
Clopidogrel was continued at 75 mg/d orally for at
least 1 month, and aspirin was continued indefinitely.
Postoperative neurologic examinations were per-
formed by vascular surgeons, residents, fellows, and recov-
ery room nurses. A postoperative physical examination and
a carotid duplex scan were repeated in all patients at 1, 6,
and 12 months, and yearly thereafter.
Technical failure was defined as inability to access or to
cross the lesion or inability to complete the procedure for
any reason. A TIA was defined as a focal hemispheric deficit
that resolved 24 hours, and a focal deficit lasting 24
hours was defined as a stroke. Recurrent or residual in-stent
stenosis was defined as 50% diameter reduction as deter-
mined by duplex ultrasound scanning. Follow-up was con-
ducted at 1, 6, 12, 24, and 36 months after surgery and
included bilateral carotid artery duplex ultrasound imaging.
Statistical analysis. This was an observational, non-
comparative study. The statistical analysis was based on
Fig 1. Diagrammatic representation of the technique used for
transcervical carotid flow reversal during carotid stenting. (Illustra-
tion by Juan Fontcuberta, MD.)descriptive statistical techniques on an intent-to-treat basis.
fter tra
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RESULTS
No patients died. Technical success was achieved in
100 (97%) cases. The three technical failures (3%) were
immediately converted to carotid endarterectomy under
general anesthesia: one because of a common carotid dis-
section with the entry sheath, one because of the inability to
cross a very tight and angulated ICA origin lesion with the
guide-wire, and one because of severe patient agitation that
required conversion to general anesthesia and the surgeon
chose to proceed with an endarterectomy rather than to
pursue the stenting procedure.
There were no major strokes. Neurologic complica-
tions occurred in four patients and included one ipsilateral
motor TIA, one contralateral TIA, and two minor strokes
(2%). One of these was in a patient with a previous ipsilat-
eral stroke who developed worsening hemiparesis, and
another patient sustained dysarthria. Both patients re-
turned to their baseline neurologic status within a week.
Two neurologic events were apparent in the operating
room and two in the recovery room. No in-hospital myo-
cardial infarctions were recorded; however, routine tropo-
nin level determinations were not obtained in the patients.
The major adverse eventrate was 0%.
Completion arteriography revealed one ICA (30%) re-
sidual stenosis and demonstrated that the external carotid
artery remained patent in all cases. Among the first 12 cases,
four common carotid artery dissections occurred at the
access site. One required surgical repair with a proximal
common carotid interposition graft, and three resolved
after placement of the stent intended to treat the stenosis
without additional stenting. During the remaining 91 pro-
cedures, one common carotid artery dissection occurred at
vessel entry, which prompted one of the conversions to
Table II. Primary patency of 103 carotid stents based on
Interval
(mon)
Entering this
interval
Exposed to
risk
Lost to
follow-up
0-1 103 103 0
1-4 100 99.5 1
4-7 97 97 0
7-10 94 94 0
10-13 90 89.5 1
13-16 86 85.5 1
16-19 81 81 0
19-22 77 77 0
22-25 72 72 0
25-28 67 67 0
28-31 66 65 2
31-34 62 61.5 1
34-37 58 58 0
37-40 53 52.5 1
*Life-table analysis, on an intention-to-treat basis, of stent primary patency a
to conversions to endarterectomy and not to stent occlusions.endarterectomy. Two postoperative wound hematomas re-quired surgical drainage under local anesthesia, but neither
required blood transfusion nor delayed the patient’s dis-
charge from the hospital. No wound infections occurred.
Mean carotid flow reversal time was 21 minutes (range,
7 to 60 minutes). Three of the 72 patients (4%) who
underwent the procedure with local anesthesia did not
tolerate carotid flow reversal and became agitated or unre-
sponsive. In one patient, the procedure was completed with
antegrade flow without protection; in the second patient,
the situation was solved with intermittent rather than con-
tinuous carotid flow reversal, allowing antegrade cerebral
flow in between carotid instrumentation maneuvers; and
the third patient was converted to endarterectomy.
Bradycardia or hypotension, or both, requiring phar-
macologic intervention occurred in response to carotid
balloon dilatation in 24 cases (23%). Two patients became
asystolic during balloon dilatation, one despite premedica-
tion with atropine, but both responded immediately to a
precordial thump. Their troponin levels were not elevated.
One of these patients required elective implantation of a
pacemaker several days after CAS secondary to an underly-
ing conduction block. Two patients became severely hyper-
tensive in response to carotid balloon inflation. In addition,
three patients became transiently unresponsive upon bal-
loon inflation during stent postdilatation.
During follow-up at 3 to 40 months, all patients re-
mained neurologically unchanged, and carotid ultrasound
revealed that all but one carotid stent remained patent
without recurrent stenosis. No cranial nerve injuries were
identified. No stenoses or pseudoaneurysms were found in
the common carotid puncture site. Five patients died dur-
ing the follow-up period; three of causes not related to
stroke, and the cause of death in two patients could not be
determined. Seven patients were lost to follow-up. No
patients progressed to renal failure during follow-up. One
carotid stent was occluded at 1 month after intervention;
no unusual circumstances occurred during the procedure.
tion to treat*
eath
Failed
stents, No.
Interval patency
rate
Cumulative
patency
0 3 0.97 0.97
0 0 1 0.97
0 1 0.98 0.95
1 0 1 0.95
0 0 1 0.95
0 0 1 0.95
0 0 1 0.95
2 0 1 0.95
0 0 1 0.95
0 0 1 0.95
0 0 1 0.95
1 0 1 0.95
1 0 1 0.95
0 0 1 0.95
nscervical stenting. The three failed stents from the first interval correspondinten
DLife-table analysis of primary stent patency, on an intention-
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free patient survival was 91% (Fig 2).
DISCUSSION
Cerebral embolization is a common event during ca-
rotid instrumentation maneuvers. This is demonstrated by
the abundant embolic signals detected by transcranial
Doppler (TCD) imaging in the middle cerebral artery
during CAS without protection.15,16 Not surprisingly,
CAS without protection is associated with a 15% to 57%
incidence of new, mostly asymptomatic, ipsilateral brain
infarcts detected by postoperative magnetic resonance im-
aging (MRI).17-19 The use of distal carotid filters for cere-
bral protection during CAS decreases the incidence of
cerebral embolization.20-23 However, distal filters require
crossing the carotid lesion before protection is in place,
probably the most emboligenic maneuver necessary for the
procedure.15,16 This is perhaps the reason why the inci-
dence of newMRI-detected brain infarction after CAS with
distal filter protection is 26% to 41%, a similar rate to that
occurring during CAS without cerebral protection.6-8
The clinical significance of the embolic phenomena
during CAS is not well known, but a clear association exists
between intraprocedural embolization and postprocedural
brain infarction. With this in mind, it would be reasonable
to expect that the use of a cerebral protection method that
would eliminate intraprocedural embolization would likely
produce a decrease in embolic-related neurologic compli-
cations after CAS.
Carotid flow reversal has shown to suppress cerebral
embolic signals during CAS in vitro and in patients and
could potentially eliminate embolic complications during
CAS.9-11 The additional unique advantages of transcervical
CAS with carotid flow reversal were extensively discussed in
our previous report.12 The technical advantages of the
procedure are that flow reversal is in place before the carotid
lesion is crossed, it avoids the femoral access, and avoids
arch and supra-aortic trunk instrumentation and any other
Fig 2. Life-table analysis of stroke-free patient survival after tran-
scervical carotid stenting.unfavorable anatomy between the femoral arteries and thecommon carotids. In addition, it enhances carotid flow
reversal throughout the procedure by using a larger caliber
fistula and a shorter, lower resistance arteriovenous com-
munication than that provided by a transfemoral flow re-
versal catheter. It is therefore plausible that the transcervical
approach may produce more effective embolic suppression.
The transcervical route also eliminates the embolic compli-
cations related to the performance of angiographic catheter
manipulations necessary during transfemoral procedures,
which may be associated with a significant incidence of new
brain infarcts detected by MRI.24
The unique features of the transcervical approach for
CAS perhaps explain the absence of major neurologic ad-
verse events in our patients, despite being an initial experi-
ence with a newly devised technique. Our expanded expe-
rience with absence of major adverse events compares
favorably with the combined death/major stroke rates
for the recently published Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE),3 ACCULINK for Revascularization of Ca-
rotids in High-Risk Patients (ARCHer),4 and Endarterec-
tomy Versus Angioplasty in Patients With Symptomatic
Severe Carotid Stenosis (EVA-3S)5 carotid stenting trials,
which were 1.8%, 3.6%, and 3.5%, respectively (Table III),
a death/stroke rate statistically not different from that of
their respective carotid endarterectomy cohorts. It is disap-
pointing that these large, complex, and costly trials have
eluded the analysis of cerebral embolization rates and of the
incidence of new MRI-detected infarction of the brain.
These unexplored study end points, directly related to the
target organ of carotid intervention, would have been
helpful in assessing the efficacy of distal filter protection in
preventing brain infarction. Unfortunately, our study also
lacks postoperative MRI evaluation.
If we assume that most major strokes during CAS are
the result of periprocedural embolization, we could specu-
late that the elimination of emboli during the procedure
could possibly reduce the major stroke rate to levels signif-
icantly lower than those achieved with carotid endarterec-
tomy, a currently elusive goal. Because of the already low
stroke rates achieved by both procedures, a confirmation of
this hypothesis would, unfortunately, require a very large
comparison trial.
The influence of the type of stent used on the results of
CAS has not been well investigated. The use of closed-cell
stents has been suggested to be associated with a lower
neurologic complication rate, a factor that could have
potentially influenced our results in a positive manner.25
Our technical success rate was 97%, comparable with
those reported in the above-mentioned major CAS trials
with much larger experiences. We found no anatomic con-
traindications for the procedure in this series. However, we
preoperatively evaluate the common carotid artery with
duplex scanning, and we do not recommend the technique
in patients with significant stenosis, calcification, or aneu-
rysmal dilatation of the proximal common carotid artery.
The neurologic tolerance to carotid flow reversal was
excellent in our experience. Only three of 72 patients (4%)
ARCH
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not tolerate carotid flow reversal. All three patients had
recently symptomatic (2 months) carotid lesions, but
only two of these three patients had contralateral ICA
occlusion, accounting for a 20% intolerance to carotid flow
reversal among 10 patients with contralateral ICA occlu-
sion. This was an almost identical intolerance rate to that
reported with carotid clamping during endarterectomy un-
der local anesthesia in patients with contralateral ICA oc-
clusion.26 Contralateral ICA occlusion with recent ipsilat-
eral hemispheric symptoms, therefore, may be a relative
contraindication to carotid flow reversal under local anes-
thesia. We have learned, however, that tolerance to flow
reversal may be improved by reversing flow intermittently
during short periods of time while carotid instrumentation
is done and allowing antegrade flow in between maneuvers.
Our expanded experience has shown a decrease in the
rate of hypotensive response to carotid balloon dilatation.
This is likely secondary to the more liberal use of premed-
ication with atropine in the later part of our experience. It is
now our practice to premedicate all patients with atropine
shortly before balloon dilatation.
The need for a surgical arterial cutdown could be
considered a drawback of our technique; however, the
wound complication rate was only 2%, comparable with the
2.6% access complication rate documented in the ARCHer
trial.4 In the ARCHer trial, however, most femoral access
site complications required blood transfusion, which was
never the case with our technique.
In our expanded experience, the complication rate has
remained low. Complications related to direct arterial
puncture for carotid access decreased significantly with
experience. During our first 12 interventions, direct carotid
puncture caused four common carotid dissections: three
were minor and corrected with the stent placement in-
tended for CAS, and one required surgical correction. Only
one dissection occurred during the last 91 cases, which was
converted immediately to an uneventful carotid endarter-
ectomy at the surgeon’s discretion. It appears, therefore,
that the learning curve may be associated with technical
complications mainly related to direct arterial puncture
leading to common carotid dissection, without being asso-
ciated with neurologic complications.
During the 3-year follow-up, our stent patency rate has
been remarkably high, and no carotid reinterventions were
Table III. Comparison table of results from this study wit
Study CAS cases, No. Death Major stro
SAPPHIRE 167 1.2 0.6
EVA-3S 265 0.8 2.7
ARCHer 581 2.1 1.5
Present 103 0 0
CAS, carotid artery stenting; SAPPHIRE, Stenting and Angioplasty with P
Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis;needed. In a similar fashion, the stroke-free survival of ourpatients was comparable, if not superior, to that reported in
the ARCHer trial.4 Our study is, admittedly, limited by the
sample size and the lack of prospective exhaustive controls
that are typical in large trials. Our results, however, suggest
that carotid flow reversal can yield very low neurologic
complication rates during CAS, potentially lower than
those achieved with distal filter protection. If carotid flow
reversal by the transcervical or any other route could elim-
inate the risk of cerebral embolization during CAS, it is
plausible that it could achieve lower neurologic complica-
tion rates than those of CAS with distal filter protection.
Carotid stenting could therefore become a safer procedure
and possibly could achieve lower neurologic complication
rates than carotid endarterectomy. These speculative hy-
potheses warrant a prospective controlled investigation.
CONCLUSION
Carotid artery stenting is an evolving technique. We are
convinced that with improved protection methods, optimi-
zation of stents and delivery systems, and refined tech-
nique, CAS will achieve better results than those currently
available. Distal filters offer limited protection, and are far
from the ideal method for cerebral protection during
CAS.6-8 We need to continue to investigate alternative
techniques and technologies to improve on the results of
CAS.
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